Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working group

CH Takimoto, SC Remick, S Sharma, S Mani… - Seminars in …, 2003 - Elsevier
Oxaliplatin is an approved agent with clinical activity in the treatment of advanced colorectal
cancer. Preliminary pharmacokinetic evidence suggests that oxaliplatin is predominantly …
被引用次数：40 相关文章

Administration of oxaliplatin to patients with renal dysfunction: A preliminary report of the National Cancer Institute Organ Dysfunction Working Group

CH Takimoto, SC Remick, S Sharma… - Seminars in …, 2003 - einstein.elsevierpure.com
Oxaliplatin is an approved agent with clinical activity in the treatment of advanced colorectal
cancer. Preliminary pharmacokinetic evidence suggests that oxaliplatin is predominantly …

Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working group.

CH Takimoto, SC Remick, S Sharma, S Mani… - Seminars in …, 2003 - europepmc.org
Oxaliplatin is an approved agent with clinical activity in the treatment of advanced colorectal
cancer. Preliminary pharmacokinetic evidence suggests that oxaliplatin is predominantly …

[引用][C] Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working group

C TAKIMOTO - Seminars in Oncology, 2003 - cir.nii.ac.jp
Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the
national cancer institute organ dysfunction working group | CiNii Research CiNii 国立情報学 …

Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working group

CH Takimoto, SC Remick, S Sharma… - Seminars in …, 2003 - pubmed.ncbi.nlm.nih.gov
Oxaliplatin is an approved agent with clinical activity in the treatment of advanced colorectal
cancer. Preliminary pharmacokinetic evidence suggests that oxaliplatin is predominantly …

Administration of oxaliplatin to patients with renal dysfunction: A preliminary report of the National Cancer Institute Organ Dysfunction Working Group

CH Takimoto, SC Remick, S Sharma… - Seminars in …, 2003 - mayoclinic.elsevierpure.com
Oxaliplatin is an approved agent with clinical activity in the treatment of advanced colorectal
cancer. Preliminary pharmacokinetic evidence suggests that oxaliplatin is predominantly …

[引用][C] Administration of oxaliplatin to patients with renal dysfunction: A preliminary report of the National Cancer Institute Organ Dysfunction Working Group

CH TAKIMOTO, SC REMICK, P IVY… - Seminars in …, 2003 - pascal-francis.inist.fr
Administration of oxaliplatin to patients with renal dysfunction: A preliminary report of the National
Cancer Institute Organ Dysfunction Working Group CNRS Inist Pascal-Francis CNRS Pascal and …

Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working group

CH Takimoto, SC Remick, S Sharma, S Mani… - Seminars in …, 2003 - infona.pl
Oxaliplatin is an approved agent with clinical activity in the treatment of advanced colorectal
cancer. Preliminary pharmacokinetic evidence suggests that oxaliplatin is predominantly …

Administration of oxaliplatin to patients with renal dysfunction: A preliminary report of the National Cancer Institute Organ Dysfunction Working Group

CH Takimoto, SC Remick, S Sharma… - Seminars in …, 2003 - experts.nebraska.edu
Oxaliplatin is an approved agent with clinical activity in the treatment of advanced colorectal
cancer. Preliminary pharmacokinetic evidence suggests that oxaliplatin is predominantly …

[引用][C] Administration of oxaliplatin to patients with renal dysfunction: A preliminary report of the National Cancer Institute Organ Dysfunction Working Group

CH TAKIMOTO, SC REMICK, S SHARMA, S MANI… - Seminars in …, 2003 - Elsevier